ALLR Medical Prognosis Institute A/S

Allarity Therapeutics (ALLR): A new direction and name for Oncology Venture

Edison Investment Research Limited
Allarity Therapeutics (ALLR): A new direction and name for Oncology Venture

09-Dec-2020 / 08:46 GMT/BST

 

London, UK, 9 December 2020

Allarity Therapeutics (ALLR): A new direction and name for Oncology Venture

It has been approximately a year since the new leadership took the reins of the company and this time of unprecedented change is capped-off with a name change from Oncology Venture to Allarity Therapeutics. It has streamlined its operations, focused on its priority assets and recapitalised itself in preparation of the upcoming NDA for dovitinib and start of studies for Ixempra. We are providing our clinical and commercial outlook with a valuation of SEK1,029m or SEK5.18 per share.

 

Our valuation is lower at SEK1,029m or SEK5.18 per share from SEK1,156m or SEK5.98 due to exchange rate effects and offset by increased net cash (estimated SEK20.2m from estimated SEK10.9m) following a recent offering through the company's equity facility with Global Corporate Finance (5.37m shares at SEK1.74). We have additionally rolled forward our NPVs and updated our clinical timelines. We expect the company to need DKK870m in additional capital to reach profitability in 2024, including a projected DKK90m before the end of 2020. 


to view the full report.

 

to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the .

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway. 

 

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube       


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1153827  09-Dec-2020 

fncls.ssp?fn=show_t_gif&application_id=1153827&application_name=news&site_id=research_pool
EN
09/12/2020

Underlying

ALLRMedical Prognosis Institute A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medical Prognosis Institute A/S

Sean Conroy
  • Sean Conroy
ALLR Medical Prognos...

Allarity Therapeutics - Termination of coverage

Edison Investment Research is terminating coverage on PIERER Mobility (PMAG), Allarity Therapeutics (ALLR), WANdisco (WAND), Quantum Genomics (ALQGC), and Mondo TV (MTVI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

ALLR MEDICAL PROGNOSIS INSTITUTE A/S
03/22/22 March 22, 2022 1 EN
 PRESS RELEASE
Free
ALLR Medical Prognos...

Allarity Therapeutics Announces Delisting and Last Day of Trading in t...

Allarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North Press release Hørsholm, Denmark (December 13, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that Nasdaq First North Growth Market Sweden (“Nasdaq First North”) has accepted the Company’s application to delist the shares of Allarity A/S. Allarity A/S submitted the application immediately after publishing the Company’s press release of December 11, 2021, announcing the intention to delist. Nasdaq First North has published its decision (668...

December 13, 2021 1 EN
 PRESS RELEASE
Free
ALLR Medical Prognos...

Allarity Therapeutics Announces Shareholder Acceptance of Share Swap O...

Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North Press release   Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders have accepted the Share Swap Offer, announced on November 24 and expired on December 9, pending final reconciliation. Considering the very high acceptance rate, the Board of Directors has as of today resolved to complete the Share Swap Offer. More...

December 11, 2021 1 EN
 PRESS RELEASE
Free
ALLR Medical Prognos...

Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire...

Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity A/S" or the "Company") hereby announces a voluntary offer and offer document to the shareholders of Allarity A/S to acquire all shares in Allarity A/S (the "Offer"), with the intent of completing the Company's recapitalization and reorganization ("Recapitalization") into a US holding company (Allarity Therapeutics, I...

November 24, 2021 1 EN
 PRESS RELEASE
Free
ALLR Medical Prognos...

Grant of New Warrants and Resolutions on Existing Warrants

Grant of New Warrants and Resolutions on Existing Warrants Company Announcement Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the Board of Directors of Allarity has exercised the authorization granted by the shareholders at the Extraordinary General Meeting held on November 22, 2021, to issue new warrants. The Board has resolved to grant a total of 51,292,653 warrants as a part of a new incentive program for the Board of Directors, employees and consultants in Allarity. All warrants are issued free of charge and are i...

November 24, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch